Caprock Group’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.12M | Sell |
7,339
-702
| -9% | -$450K | 0.1% | 178 |
|
|
2025
Q4 | $5.44M | Buy |
8,041
+320
| +4% | +$218K | 0.11% | 142 |
|
|
2025
Q3 | $5M | Buy |
+7,721
| New | +$4.69M | 0.12% | 138 |
|
|
2025
Q1 | $2.42M | Buy |
5,762
+3,745
| +186% | +$1.63M | 0.07% | 244 |
|
|
2024
Q4 | $834K | Sell |
2,017
-730
| -27% | -$320K | 0.03% | 473 |
|
|
2024
Q3 | $1.39M | Sell |
2,747
-106
| -4% | -$51.5K | 0.05% | 316 |
|
|
2024
Q2 | $1.39M | Buy |
2,853
+717
| +34% | +$360K | 0.06% | 296 |
|
|
2024
Q1 | $1.15M | Sell |
2,136
-5,212
| -71% | -$2.85M | 0.07% | 220 |
|
|
2023
Q4 | $4.08M | Buy |
7,348
+5,324
| +263% | +$2.5M | 0.26% | 59 |
|
|
2023
Q3 | $885K | Sell |
2,024
-125
| -6% | -$62.3K | 0.07% | 236 |
|
|
2023
Q2 | $1.08M | Buy |
2,149
+198
| +10% | +$94.9K | 0.08% | 202 |
|
|
2023
Q1 | $976K | Buy |
1,951
+142
| +8% | +$68K | 0.08% | 207 |
|
|
2022
Q4 | $738K | Buy |
1,809
+184
| +11% | +$71.4K | 0.07% | 220 |
|
|
2022
Q3 | $529K | Buy |
1,625
+13
| +0.8% | +$4.78K | 0.05% | 269 |
|
|
2022
Q2 | $565K | Sell |
1,612
-51
| -3% | -$20.8K | 0.06% | 249 |
|
|
2022
Q1 | $910K | Sell |
1,663
-126
| -7% | -$66.3K | 0.09% | 189 |
|
|
2021
Q4 | $1.18M | Buy |
1,789
+145
| +9% | +$91K | 0.1% | 150 |
|
|
2021
Q3 | $1.02M | Buy |
1,644
+404
| +33% | +$271K | 0.09% | 151 |
|
|
2021
Q2 | $783K | Sell |
1,240
-18
| -1% | -$9.94K | 0.07% | 194 |
|
|
2021
Q1 | $616K | Buy |
1,258
+9
| +0.7% | +$4.51K | 0.07% | 207 |
|
|
2020
Q4 | $624K | Sell |
1,249
-70
| -5% | -$31.3K | 0.07% | 201 |
|
|
2020
Q3 | $519K | Buy |
1,319
+74
| +6% | +$27.4K | 0.07% | 198 |
|
|
2020
Q2 | $411K | Buy |
+1,245
| New | +$360K | 0.06% | 224 |
|
|
2018
Q4 | – | Sell |
-929
| Closed | -$232K | – | 382 |
|
|
2018
Q3 | $232K | Sell |
929
-820
| -47% | -$199K | 0.05% | 328 |
|
|
2018
Q2 | $381K | Sell |
1,749
-57
| -3% | -$11.7K | 0.08% | 228 |
|
|
2018
Q1 | $346K | Sell |
1,806
-17
| -0.9% | -$3.14K | 0.07% | 239 |
|
|
2017
Q4 | $316K | Sell |
1,823
-48
| -3% | -$7.55K | 0.06% | 283 |
|
|
2017
Q3 | $291K | Buy |
1,871
+41
| +2% | +$6.48K | 0.06% | 299 |
|
|
2017
Q2 | $295K | Buy |
1,830
+40
| +2% | +$6.5K | 0.07% | 284 |
|
|
2017
Q1 | $277K | Hold |
1,790
| – | – | 0.07% | 263 |
|
|
2016
Q4 | $210K | Hold |
1,790
| – | – | 0.05% | 303 |
|
|
2016
Q3 | $202K | Buy |
+1,790
| New | +$189K | 0.05% | 329 |
|
Other funds holding IDXX
VCM
VPM
Caprock Group's IDXX Position: Q1 2026 in Review
Caprock Group reduced its Idexx Laboratories (IDXX) stake by 8.7% in Q1 2026, selling an estimated $450K and leaving 7,339 shares worth $4.12M. The position accounts for 0.1% of the portfolio, ranked #178.
Caprock Group first reported a position in IDXX in Q3 2016 and has held it in 32 quarters since. The position peaked at $5.44M in Q4 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Caprock Group held 7,339 shares of Idexx Laboratories worth $4.12M as of Q1 2026.
- Caprock Group sold 702 Idexx Laboratories shares in Q1 2026, an estimated $450K.
- Idexx Laboratories made up 0.1% of Caprock Group's portfolio in Q1 2026, its #178 holding.
- Caprock Group first reported a position in Idexx Laboratories in Q3 2016 and has held it in 32 quarters since.
- Caprock Group's Idexx Laboratories position peaked at $5.44M in Q4 2025.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.